Page last updated: 2024-08-25

1-cyclohexyl-3-(2-(4-morpholinyl)ethyl)carbodiimide and Spinal Cord Diseases

1-cyclohexyl-3-(2-(4-morpholinyl)ethyl)carbodiimide has been researched along with Spinal Cord Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Berardi, A; Echavarría-Íñiguez, A; Galeoto, G; García-López, B; Gómez-Menéndez, AI; González-Bernal, J; González-Santos, J; Isidro-Mesas, F; Lloria-Gil, MDC; Martín-Alonso, J; Tofani, M; Vázquez-Sánchez, F1
Chang, Y; Chen, C; Ye, Y; Yu, T; Yu, Z; Zeng, S; Zhan, S; Zheng, X; Zou, X1

Other Studies

2 other study(ies) available for 1-cyclohexyl-3-(2-(4-morpholinyl)ethyl)carbodiimide and Spinal Cord Diseases

ArticleYear
The Role of Magnetic Transcranial Stimulation in the Diagnosis and Post-Surgical Follow-Up of Cervical Spondylotic Myelopathy.
    International journal of environmental research and public health, 2023, 02-19, Volume: 20, Issue:4

    Topics: Cervical Vertebrae; Evoked Potentials, Motor; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Retrospective Studies; Spinal Cord Compression; Spinal Cord Diseases

2023
Electrophysiological evidence of diabetes' impacts on central conduction recoveries in degenerative cervical myelopathy after surgery.
    European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2023, Volume: 32, Issue:6

    Topics: Cervical Vertebrae; Diabetes Mellitus; Humans; Insulins; Spinal Cord Diseases; Treatment Outcome

2023